Patents by Inventor Kurt G. Pike

Kurt G. Pike has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Fused 1,4-dihydrodioxin derivatives as inhibitors of heat shock transcription factor 1
    Patent number: 11787786
    Abstract: The present invention relates to compounds of formula I wherein A1, A2 R4 and Q are as defined herein. The compounds of the present invention are inhibitors of heat shock factor 1 (HSF1). In particular, the present invention relates to the use of these compounds as therapeutic agents for the treatment and/or prevention of proliferative diseases, such as cancer. The present invention also relates to processes for the preparation of these compounds, and to pharmaceutical compositions comprising them.
    Type: Grant
    Filed: August 19, 2021
    Date of Patent: October 17, 2023
    Assignee: CANCER RESEARCH TECHNOLOGY LIMITED
    Inventors: Keith Jones, Carl Rye, Nicola Chessum, Matthew D. Cheeseman, Adele E. Pasqua, Kurt G. Pike, Paul F. Faulder
  • FUSED 1,4-DIHYDRODIOXIN DERIVATIVES AS INHIBITORS OF HEAT SHOCK TRANSCRIPTION FACTOR 1
    Publication number: 20220220097
    Abstract: The present invention relates to compounds of formula I wherein A1, A2 R4 and Q are as defined herein. The compounds of the present invention are inhibitors of heat shock factor 1 (HSF1). In particular, the present invention relates to the use of these compounds as therapeutic agents for the treatment and/or prevention of proliferative diseases, such as cancer. The present invention also relates to processes for the preparation of these compounds, and to pharmaceutical compositions comprising them.
    Type: Application
    Filed: August 19, 2021
    Publication date: July 14, 2022
    Inventors: Keith Jones, Carl Rye, Nicola Chessum, Matthew D. Cheeseman, Adele E. Pasqua, Kurt G. Pike, Paul F. Faulder
  • Fused 1,4-dihydrodioxin derivatives as inhibitors of heat shock transcription factor I
    Patent number: 11124501
    Abstract: The present invention relates to compounds of formula I as defined herein. The compounds of the present invention are inhibitors of heat shock factor 1 (HSF1). In particular, the present invention relates to the use of these compounds as therapeutic agents for the treatment and/or prevention of proliferative diseases, such as cancer. The present invention also relates to processes for the preparation of these compounds, and to pharmaceutical compositions comprising them.
    Type: Grant
    Filed: December 6, 2018
    Date of Patent: September 21, 2021
    Assignee: CANCER RESEARCH TECHNOLOGY LIMITED
    Inventors: Keith Jones, Carl Rye, Nicola Chessum, Matthew Cheeseman, Adele E. Pasqua, Kurt G. Pike, Paul F. Faulder
  • INHIBITOR COMPOUNDS
    Publication number: 20190106413
    Abstract: The present invention relates to compounds of formula I as defined herein. The compounds of the present invention are inhibitors of heat shock factor 1 (HSF1). In particular, the present invention relates to the use of these compounds as therapeutic agents for the treatment and/or prevention of proliferative diseases, such as cancer. The present invention also relates to processes for the preparation of these compounds, and to pharmaceutical compositions comprising them.
    Type: Application
    Filed: December 6, 2018
    Publication date: April 11, 2019
    Inventors: Keith Jones, Carl Rye, Nicola Chessum, Matthew Cheeseman, Adele E, Pasqua, Kurt G, Pike, Paul F. Faulder
  • Fused 1,4-dihydrodioxin derivatives as inhibitors of heat shock transcription factor I
    Patent number: 10189821
    Abstract: The present invention relates to compounds of formula I as defined herein. The compounds of the present invention are inhibitors of heat shock factor 1 (HSF1). In particular, the present invention relates to the use of these compounds as therapeutic agents for the treatment and/or prevention of proliferative diseases, such as cancer. The present invention also relates to processes for the preparation of these compounds, and to pharmaceutical compositions comprising them.
    Type: Grant
    Filed: October 24, 2016
    Date of Patent: January 29, 2019
    Assignee: Cancer Research Technology Limited
    Inventors: Keith Jones, Carl Rye, Nicola Chessum, Matthew Cheeseman, Adele E. Pasqua, Kurt G. Pike, Paul F. Faulder
  • Fused 1,4-dihydrodioxin derivatives as inhibitors of heat shock transcription factor 1
    Patent number: 9701664
    Abstract: The present invention relates to compounds of formula I as defined herein. The compounds of the present invention are inhibitors of heat shock factor 1 (HSF1). In particular, the present invention relates to the use of these compounds as therapeutic agents for the treatment and/or prevention of proliferative diseases, such as cancer. The present invention also relates to processes for the preparation of these compounds, and to pharmaceutical compositions comprising them.
    Type: Grant
    Filed: October 3, 2014
    Date of Patent: July 11, 2017
    Assignee: CANCER RESEARCH TECHNOLOGY LIMITED
    Inventors: Keith Jones, Carl Rye, Nicola Chessum, Matthew Cheeseman, Adele E. Pasqua, Kurt G. Pike, Paul F. Faulder
  • FUSED 1,4-DIHYDRODIOXIN DERIVATIVES AS INHIBITORS OF HEAT SHOCK TRANSCRIPTION FACTOR I
    Publication number: 20170037036
    Abstract: The present invention relates to compounds of formula I as defined herein. The compounds of the present invention are inhibitors of heat shock factor 1 (HSF1). In particular, the present invention relates to the use of these compounds as therapeutic agents for the treatment and/or prevention of proliferative diseases, such as cancer. The present invention also relates to processes for the preparation of these compounds, and to pharmaceutical compositions comprising them.
    Type: Application
    Filed: October 24, 2016
    Publication date: February 9, 2017
    Inventors: Keith Jones, Carl Rye, Nicola Chessum, Matthew Cheeseman, Adele E. Pasqua, Kurt G. Pike, Paul F. Faulder
  • FUSED 1,4-DIHYDRODIOXIN DERIVATIVES AS INHIBITORS OF HEAT SHOCK TRANSCRIPTION FACTOR 1
    Publication number: 20160289216
    Abstract: The present invention relates to compounds of formula I as defined herein. The compounds of the present invention are inhibitors of heat shock factor 1 (HSF1). In particular, the present invention relates to the use of these compounds as therapeutic agents for the treatment and/or prevention of proliferative diseases, such as cancer. The present invention also relates to processes for the preparation of these compounds, and to pharmaceutical compositions comprising them.
    Type: Application
    Filed: October 3, 2014
    Publication date: October 6, 2016
    Inventors: Keith Jones, Carl Rye, Nicola Chessum, Matthew Cheeseman, Adele E. Pasqua, Kurt G. Pike, Paul F. Faulder